World's Best Scientists 2026 revealed!
Gunnar B. Kristensen

Gunnar B. Kristensen

D-Index & Metrics

Medicine

D-Index
83
Citations
30475
World Ranking
15458
National Ranking
72

Gunnar B. Kristensen publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Gunnar B. Kristensen sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 319 publications — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Gunnar B. Kristensen D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Gunnar B. Kristensen sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Gunnar B. Kristensen is affiliated with Oslo University Hospital in Norway and has contributed extensively to the field of medicine with a focus on reproductive health and oncology. Their academic work spans several subfields including reproductive medicine, obstetrics and gynecology, radiology, nuclear medicine and imaging, pulmonary and respiratory medicine, and oncology.

Their research is centered around key topics such as endometrial and cervical cancer treatments, ovarian cancer diagnosis and treatment, MRI in cancer diagnosis, endometriosis research and treatment, radiomics and machine learning in medical imaging, renal cell carcinoma treatment, and the interplay between cancer, hypoxia, and metabolism.

Recent publications by Kristensen include:

  • MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum (2020, Journal of Clinical Oncology)
  • Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification (2021, Cancers)
  • Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994 (2023, Journal of Clinical Oncology)
  • Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer (2020, JAMA Network Open)
  • MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer (2020, Cancer Research)

Kristensen's frequent co-authors reflect collaborative work within the medical research community and include:

  • Kristina Lindemann
  • Hanne A. Askautrud
  • Andreas Kleppe
  • Wanja Kildal
  • Manohar Pradhan

Key publication venues for their research output are:

  • International Journal of Gynecological Cancer
  • Journal of Clinical Oncology
  • Cancers
  • Gynecologic Oncology
  • European Journal of Cancer

Kristensen's body of work heavily emphasizes cancer diagnosis and treatment strategies, particularly those related to gynecological cancers. Their contributions include studies leveraging advanced imaging techniques such as MRI to assess tumor characteristics and treatment response, as well as exploring molecular classifications and biomarkers for risk stratification.

Their research output includes 73 publications in medicine with a particular impact in reproductive medicine and oncology, addressing both clinical treatment approaches and diagnostic technologies.

Best Publications

  • Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

    Ignace Vergote;Claes G. Tropé;Frédéric Amant;Gunnar B. Kristensen

  • A phase 3 trial of bevacizumab in ovarian cancer.

    Timothy J Perren;Ann Marie Swart;Jacobus Pfisterer;Jonathan A Ledermann

  • Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

    Eric Pujade-Lauraine;Felix Hilpert;Beatrice Weber;Alexander Reuss

  • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

    MK Parmar;JA Ledermann;N Colombo;Bois A Du

  • Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

    Amit M. Oza;Adrian D. Cook;Jacobus Pfisterer;Andrew Embleton

  • Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers

    Jen Tsan Chi;Jen Tsan Chi;Zhen Wang;Dimitry S.A. Nuyten;Edwin H. Rodriguez

  • Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.

    Gordon J.S. Rustin;Maria E.L. Van Der Burg;Clare L. Griffin;David Guthrie

  • Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

    Eric Pujade-Lauraine;Uwe Wagner;Elisabeth Aavall-Lundqvist;Val Gebski

  • Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

    Gordon John Sampson Rustin;Ignace Vergote;Elizabeth Eisenhauer;Eric Pujade-Lauraine

  • 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

    A du Bois;M Quinn;T Thigpen;J Vermorken

  • Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer - Results from two randomised studies

    Thomas Hogberg;Mauro Signorelli;Carlos Freire de Oliveira;Roldano Fossati

  • Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients

    Vera M Abeler;Odd Røyne;Steinar Thoresen;Håvard E Danielsen

  • Gene Expression Patterns in Ovarian Carcinomas

    Marci E. Schaner;Douglas T. Ross;Giuseppe Ciaravino;Therese Sørlie

  • Use of multiple PCR primer sets for optimal detection of human papillomavirus.

    Frank Karlsen;Mina Kalantari;Andy Jenkins;Erik Pettersen

  • The Prognostic Significance of Residual Disease, FIGO Substage, Tumor Histology, and Grade in Patients with FIGO Stage III Ovarian Cancer

    Amin Ph. Makar;Mark Baekelandt;Claes O. Tropé;Gunnar B. Kristensen

  • Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.

    I Vergote;G J Rustin;E A Eisenhauer;G B Kristensen

  • Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.

    I Vergote;C Coens;M Nankivell;G B Kristensen

  • Tumor Size, Depth of Invasion, and Grading of the Invasive Tumor Front Are the Main Prognostic Factors in Early Squamous Cell Cervical Carcinoma

    Gunnar B. Kristensen;Vera M. Abeler;Bjørn Risberg;Claes Tropé

  • Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers

    Åslaug Helland;Michael S. Anglesio;Michael S. Anglesio;Joshy George;Joshy George;Prue A. Cowin

  • Carcinoma of the fallopian tube.

    Mark Baekelandt;Anne Jorunn Nesbakken;Gunnar B. Kristensen;Claes G. Tropé

Frequent Co-Authors

Claes G. Tropé
Claes G. Tropé University of Oslo
Jahn M. Nesland
Jahn M. Nesland Oslo University Hospital
Ben Davidson
Ben Davidson Oslo University Hospital
Anne Lise Børresen-Dale
Anne Lise Børresen-Dale Oslo University Hospital
Sandro Pignata
Sandro Pignata National Cancer Institute
Andreas du Bois
Andreas du Bois Johannes Gutenberg University of Mainz
Val Gebski
Val Gebski University of Sydney
Jonathan A. Ledermann
Jonathan A. Ledermann University College London
Iris Goldberg
Iris Goldberg Sheba Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t always require a traditional MD path. There are various online msn pmhnp programs available for those interested in mental health care. These programs prepare nurses for advanced roles in psychiatric care and can often be completed in an accelerated format.

For students interested in the administrative side of healthcare, a health care administration degree online provides a flexible way to build vital leadership and management skills. These degrees open doors to in-demand roles in hospitals, clinics, and healthcare organizations.

Cost is always a consideration. Exploring options for the mha degree cost can help you find affordable master’s programs in healthcare administration, allowing you to advance your career without taking on excessive debt.

For those aiming even higher, you might consider cheap dnp online programs to reach the highest clinical levels in nursing. These programs are designed for working professionals seeking flexibility and affordability.

Online degrees make it easier than ever to pursue these rewarding healthcare pathways, whether your passion lies in direct patient care, mental health, or healthcare leadership.

Best Scientists Citing Gunnar B. Kristensen

Trending Scientists

Recently Published Articles